AgomAb Therapeutics NV
AGMBNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $339.56M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $7.97$17.82
- Volume (live)
- -
- Avg. volume (3M)
- 153.49K
AgomAb Therapeutics NV (AGMB) Stock Price & Financial Analysis
AgomAb Therapeutics NV Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $7.92 - $8.53 |
|---|---|
| 52-Week High | $17.82 |
| 52-Week Low | $7.97 |
| Open | $8.21 |
| Volume (last close) | 78.13K |
| Average Volume (3M) | 153.49K |
| 50-Day MA | $12.25 |
|---|
| Market Cap | 339.56M |
|---|---|
| Shares Outstanding | 40.76M |
| Price to Book (P/B) | 1.14 |
| EV/EBITDA | -1.18 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
AgomAb Therapeutics NV at a Glance
As of the Oct 16, 2026 close, AgomAb Therapeutics NV (AGMB) has a market capitalization of $339.56M.
As of its latest reported balance sheet, it holds $249.05M in cash and securities against $1.02M of debt, a net cash position of $248.02M.
AgomAb Therapeutics NV does not currently pay a dividend.
At $8.28 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $7.97 to $17.82.
Based on 7 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $35.00, 322.7% above the Oct 16, 2026 close.
Frequently Asked Questions About AgomAb Therapeutics NV
What is the current stock price for AGMB?
As of the Oct 16, 2026 close, AGMB stock trades at $8.28. The 52-week range is $7.97–$17.82, with a day range of $7.92–$8.53.
What is the P/E ratio for AGMB?
The P/E ratio (Price-to-Earnings) for AGMB is shown in the Key Statistics section. This valuation metric helps compare AgomAb Therapeutics NV to industry peers.
Does AGMB pay dividends?
AgomAb Therapeutics NV does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for AGMB?
Based on ratings from 7 professional analysts over the last 90 days, the consensus for AGMB is Buy. The average 12-month price target is $35.00, a 322.7% upside from the Oct 16, 2026 close of $8.28.
What is the market cap of AGMB?
As of the Oct 16, 2026 close, AgomAb Therapeutics NV's market capitalization is $337.5M, classifying it as a small-cap company. AgomAb Therapeutics NV operates in the Healthcare sector within the Biotechnology industry.